

Dear Editor,

Thank you for your kind letter of “**World Journal of Clinical Cases Manuscript NO: 73474 – Notification on manuscript revision**” on January 12<sup>th</sup>, 2022. We revised the manuscript in accordance with the reviewers’ comments, and carefully proof-read the manuscript to minimize typographical, grammatical, and bibliographical errors.

Here below is our explanation on revision according to the reviewers’ comments.

#### Reviewer 1

The reviewer's comment: Zhai C et al. presented a case report of a patient with pMMR/MSS endometrial cancer treated with combination of a PD-1 inhibitor and a tyrosine kinase inhibitor. The authors have previously reported the efficacy and safety of the combination treatment for non-small cell lung cancer (Front Oncol 2021). A recurrent endometrial cancer after chemotherapies were treated with a novel PD-1 inhibitor toripalimab. Eventually the combination of the PD-1 inhibitor and a tyrosine kinase inhibitor, anlotinib successfully diminished lung metastasis. The characteristics of the metastatic tumor, analyses with immunohistochemistry and genetic sequencing, were confirmed pMMR and MSS-type endometrial adenocarcinoma. This case report indicates the regime combined with a PD-1 inhibitor and a tyrosine kinase inhibitor may be effective against pMMR/MMS endometrial cancer. This well-written manuscript can be published with some minor revisions. Minor points 1. The graph in Figure 3 should be ranged from 2019 to 2021. 2. In Figure 4, treatments are indicated with arrows. The terms can be shown with rectangles or other. 3. In figure legend of Fig 2, 4/16/2020 may be a typographical error.

The authors’ Answer: Thank you for your careful reading and pointing out our mistakes, which is of great help to us. For these errors, 1. The graph in Figure 3 has been ranged from 2019 to 2021. 2. We are a little unclear about this proposal, but we have consulted other literatures and made appropriate adjustments. 3. In figure legend of Fig 2, 4/16/2020 has been corrected. Thanks again!

#### Reviewer 2

The review's comment: I read and reviewed the article entitled “A case study of PD-1 inhibitor combination treatment for recurrent pMMR/MSS-type endometrial cancer”. Abstract: “Endometrial cancer is one of the most common cancers of the female reproductive tract and its worldwide incidence has gradually increased over the past decades. PD-1 inhibitors are a group of checkpoint inhibitor anticancer drugs that block PD-1 and PD-L1 activities on the cell surface to prevent immune escape.” These two sentences should be taken as too detailed information for the abstract. Introduction: “This article includes a case study and preliminary discussion of PD-1 inhibitor immunotherapy combined with chemotherapy or anti-angiogenesis targeted therapy for a patient with pMMR/MSS recurrent EC; we further elaborate the molecular classification, choice of treatment regimen, and therapeutic efficacy.” The authors

should use “presents” term instead of “includes”. Case Presentation: “Four years later, she developed chest pain”. Pain severity, type (e.g., sharp, burning) should be given, if questioned.

The authors' Answer: Thank you very much for your valuable advice. The two sentences in abstract have been replaced by “Endometrial cancer is one of the most common cancers of the female reproductive tract, and the incidence is increasing rapidly. Immunotherapy using PD-1 inhibitors is an emerging research topic and treatment strategy for refractory gynecological malignancies”. The term “includes” in introduction has been replaced by “presents”. Case Presentation: “Four years later, she developed chest pain”. It has been changed to “Four years later, she developed persistent dull chest pain”.

We have polished the manuscript in website: <https://www.wjgnet.com/bpg/gerinfo/240>. Many grammatical or typographical errors have been revised.

We have prepared the Signed Consent for Treatment Form(s) or Document(s), the original figure documents arranged in PowerPoint, and grant application form(s) or funding agency copy of any approval document(s).

Thank you and all the reviewers for the kind advice.

Sincerely yours,  
Weidong Han